Serum levels of TNF-β and sTNF-R in patients with malignant bone tumours

Anticancer Research

Volumn 23, Issue 3 C, 2003, Pages 3057-3059

  Holzer, Gerold ^a   Pfandlsteiner, T ^a   Blahovec, H ^a   Trieb, K ^a   Kotz, R ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Ewing sarcoma; High grade osteosarcoma; Serum levels; TNF ; TNF R

Indexed keywords

ANTINEOPLASTIC AGENT; LYMPHOTOXIN; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BONE CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; EWING SARCOMA; FEMALE; HUMAN; MALE; OSTEOSARCOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SCHOOL CHILD; SERUM;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; FEMALE; HUMANS; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; OSTEOSARCOMA; RECEPTORS, TUMOR NECROSIS FACTOR; SARCOMA, EWING'S; TUMOR MARKERS, BIOLOGICAL;

EID: 0042623864     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bielack S, Kempf-Bielack B, Delling G, Exner U, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jürgens H and Winkler K: Prognostic factors in high-grade osteosarcoma of the extremities or trunk. J Clin Oncol 20: 776-790, 2002.
2. Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, Dunst J, Harms D, Reiter A, Henze G, Niemeyer C, Gobel U, Kremens B, Folsch UR, Aulitzky WE, Voute PA, Zoubek A and Jurgens H: Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol 12: 1619-30, 2001.
3. Aggarwal BB, Aiyer RA, Pennica D, Gray PW and Goeddel DV: Human tumour necrosis factors: structure and receptor interactions. Ciba-Found-Symp 131: 39-51, 1987.
4. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N and Williamson B: Anendotoxin-induced serum factor that causes necroses of tumours. Proc Natl Acad Sci USA 72: 3666-3670, 1975.
5. Old LJ: Tumour necrosis factor (TNF). Science 230: 630-632, 1985.
6. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W and Loetscher H: Identification of two types of tumour necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 87: 3127-31, 1990.
7. Spies T, Morton CC, Nedospasov SA, Fiers W, Pious D and Strominger JL: Genes for the tumour necrosis factor a and b are linked to the human major histocompatibility complex. Proc Natl Acad Sci USA 83: 8699-702, 1986.
8. Li CB, Gray PW, Lin LF, McGrath KM, Ruddle FH and Ruddle NH: Cloning and expression of murine lymphotoxin cDNA. J Immunol 138: 4496-501, 1987.
9. Paul NL and Ruddle NH: Lymphotoxin. Ann Rev Immunol 6: 407-38, 1988.
10. Bertolini DR, Nedwin GE, Bringman TS, Smith DD and Mundy GR: Stimulation of bone resorption and inhibition of bone formation in vitro by human necrosis factors. Nature 319: 516-8, 1986.
11. Ishibashi K, Ishitsuka K, Chuman Y, Otsuka M, Kuwazuru Y, Iwahashi M, Utsunomiya A, Hanada S, Sakurami T and Arima T: Tumour necrosis factor-beta in the serum of adult T-cell leukemia with hypercalcemia. Blood 77: 2451-5, 1991.
12. Mooradian AD, Reed RL, Duerr ML, Valdez C and Scuderi P: The effect of age and diabetes mellitus on serum levels of lymphotoxin. Age 15: 95-9, 1992.
13. 125I-labeled tumour necrosis factor: specific binding, affinity labeling, and relationship to sensivity. Proc Natl Acad Sci USA 82: 5756-60, 1985.
14. Thoma B, Grell M, Pfizenmaier K and Scheuerich P: Identification of 60kDa tumour necrosis factor (TNF) receptor as the major signal transducing component in TNF responses. J Exp Med 172: 1019-23, 1990.
15. Barrera P, Boerbooms A, Janssen E, Sauerwein R, Galatti H, Mulder J, de Boo T, Demacker P, van de Putte L and van der Meer J: Circulating soluble tumour necrosis f factor receptors, interleukin-2 receptors, tumour necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Arthr Rheum 36: 1070-9, 1993.
16. Gruss H, Dölken G, Brach M, Mertelsmann R and Hermann F: The significance of serum levels of soluble 60kDa receptors for tumour necrosis factor in patients with Hodgkin's Disease. Leukemia 7: 1339-43, 1993.
17. Godfried M, von der Poll J, Jansen, Romijin j, Söchattenker J, Endert E, von Deventer S and Sauerwein H: Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection. Aids 7: 33-36, 1993.
18. Enneking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcomas. Clin Orthop 153: 106-120, 1980
19. Salzer-Kuntschik M, Brand G and Delling G: Bestimmung des morphologischen regressionsgrades nach chemotherapie bei malignen knochentumoren. Pathologe 4: 135-38, 1983.
20. Meyers PA and Gorlick R: Osteosarcoma. Pediatr Clin North Am 44: 973-989, 1997